Company is advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications ...

Xenetic (XBIO) Biosciences has extended its previously announced Research Funding and Option Agreement with The Scripps Research Institute to advance the development of the Company’s program on the ...

Collaborative among FAU, Scripps, Max Planck and more intends to champion research, programming to make County hub of 'The ...

Company is advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / November 7, 2024 / Xenetic Biosciences, Inc ...

FRAMINGHAM, MA / ACCESSWIRE / November 7, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology ...

Zeit Aktuelle Nachrichten Do Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform Company is advancing DNase-based ...

Developer Todd Michael Glaser updated the 1994 house that his company just sold for $38 million to Dr. Herbert Wertheim, a ...

It is the first time spatial proteomics has been used to treat a patient. Eric Topol, director of the Scripps Research ...

In response to the outbreak of protests, David Closson, director of Family Research Council’s Center for Biblical Worldview, ...

To help address this growing challenge, scientists at Scripps Research and its nonprofit drug development arm, the Calibr-Skaggs Institute for Innovative Medicines, are advancing novel ...